Search

Your search keyword '"Dog Diseases immunology"' showing total 3,356 results

Search Constraints

Start Over You searched for: Descriptor "Dog Diseases immunology" Remove constraint Descriptor: "Dog Diseases immunology"
3,356 results on '"Dog Diseases immunology"'

Search Results

1. Expression of key cytokines in dog macrophages infected by Leishmania tarentolae opening new avenues for the protection against Leishmania infantum.

2. Preliminary field evaluation of indirect ELISA test using the recombinant antigen rLicNTPDase-2 for serodiagnosis of canine leishmaniasis in Colombia.

3. Tumor-associated macrophages and tumor-infiltrating lymphocytes in canine cutaneous and subcutaneous mast cell tumors.

4. Diagnosis of canine B-cell chronic lymphoid leukemia with a CD21 negative phenotype using the LT21 clone CD21 antibody in flow cytometry: a case report.

5. Clinical significance of blood cell ratios in healthy and sick Leishmania infantum-seropositive dogs.

6. Generation of canine neutralizing antibodies against canine parvovirus by single B cell antibody technology.

7. Saurian-associated Leishmania tarentolae in dogs: Infectivity and immunogenicity evaluation in the canine model.

8. Development of novel canine phage display-derived neutralizing monoclonal antibody fragments against rabies virus from immunized dogs.

9. Interleukin-27 Regulates Adaptative Immune Responses Associated With Control of Parasite Replication in Canine Leishmaniasis.

10. Adaptive and innate immune response of Leishmania infantum infection in Cirneco dell'Etna dog breed.

11. Translational History and Hope of Immunotherapy of Canine Tumors.

12. Allergies to Allergens from Cats and Dogs: A Review and Update on Sources, Pathogenesis, and Strategies.

13. Inflammatory and immune variables as predictors of survival in dogs with myxomatous mitral valve disease.

14. Immunohistochemical and transcriptomic characterization of T and myeloid cell infiltrates in canine malignant melanoma.

15. In silico designing of multi-epitope vaccine against canine parvovirus using reverse vaccinology.

16. Dog complement system is less effective against Leishmania infantum than human complement.

17. Determination of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in dogs with leptospirosis.

18. Rapid induction of allergen-blocking IgG in dogs vaccinated with plant-based, Der f 2-expressing bioparticles.

19. Identification of cross-reactive allergens between the Dermatophagoides farinae house dust mite and the Toxocara canis nematode in dogs with suspected allergies.

20. Macrophage Colony Stimulating Factor (M-CSF) and Interleukin-34 (IL-34) Expression in Canine Osteosarcoma in the Context of the Tumour Immune Microenvironment.

21. Comprehensive Analysis of the Tumour Immune Microenvironment in Canine Urothelial Carcinoma Reveals Immunosuppressive Mechanisms Induced by the COX-Prostanoid Cascade.

22. TGFβ in malignant canine mammary tumors: relation with angiogenesis, immunologic markers and prognostic role.

23. Discovery of new antigens for serodiagnosis of visceral leishmaniasis in humans and dogs adds valuable tools to our arsenal.

24. Seroprevalence of Leptospira antibodies in dogs and cats from Santa Fe, a city in East-Central Argentina endemic for leptospirosis.

25. Evaluation of immunophenotype and inflammation in canine mammary neoplasms with solid arrangement.

26. Modulation of MHC expression by interferon-gamma and its influence on PBMC-mediated cytotoxicity in canine mast cell tumour cells.

27. Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.

28. Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs.

29. Re-evaluating the prevalence of anti-desmocollin-1 IgA autoantibodies in canine pemphigus foliaceus.

30. The Density of CD8 + Tumor-infiltrating Lymphocytes Correlated With Akt Activation and Ki-67 Index in Canine Soft Tissue Sarcoma.

31. Identification of risk factors on rabies vaccine efficacy from censored data: Pre-travel tests for dogs and cats from Yaoundé (2005-2015).

32. Immunoexpression of IL-33 in the different clinical aspects of canine atopic dermatitis.

33. Assessment of glial fibrillary acidic protein and anti-glial fibrillary acidic protein autoantibody concentrations and necrotising meningoencephalitis risk genotype in dogs with pug dog myelopathy.

34. Single cell transcriptomic analysis of the canine duodenum in chronic inflammatory enteropathy and health.

35. Molecular insights and antibody response to Dr20/22 in dogs naturally infected with Dirofilaria repens.

36. Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.

37. A novel linear B cell epitope of the canine coronavirus nucleocapsid protein identified by a monoclonal antibody.

38. Extracellular traps development in canine neutrophils induced by infective stage Toxocara canis larvae.

39. Canine parvovirus type 2 (CPV-2) serological and molecular patterns in dogs with viral gastroenteritis from southern Brazil.

40. Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.

41. Comparative structural and immunological analysis of outer membrane proteins and dermonecrotic toxin in Bordetella bronchiseptica canine isolate.

42. Bacterial microbiota and proinflammatory cytokines in the anal sacs of treated and untreated atopic dogs: Comparison with a healthy control group.

43. Evolutionary dynamics of canine kobuvirus in Vietnam and Thailand reveal the evidence of viral ability to evade host immunity.

44. Elevated levels of IL-12/IL-23p40 in Nova Scotia Duck Tolling Retrievers with autoimmune disease and lymphoma.

45. Comparative characterization of two monoclonal antibodies targeting canine PD-1.

46. Peripheral and intestinal T lymphocyte subsets in dogs with chronic inflammatory enteropathy.

47. Quantification of CD3, FoxP3, and granzyme B immunostaining in canine renal cell carcinoma.

48. Use of human intravenous immunoglobulin for the treatment of 12 dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia.

49. PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems.

50. Evaluation of Ki-67, goblet cell and MUC2 mucin RNA expression in dogs with lymphoplasmacytic and granulomatous colitis.

Catalog

Books, media, physical & digital resources